BPC-157

TheraTide USA

$59.99 - $93.99
BPC-157
Availability:
In Stock
Adding to cart… The item has been added

Lyophilized Peptides: These peptides are freeze-dried, a process that not only extends shelf life but also preserves the purity and integrity of the peptides during storage.

Non-Lyophilized Peptides: Offered as a dry powder, these peptides, while not as extensively processed as lyophilized peptides, still maintain a high level of purity. Their stability, though not as enhanced as in lyophilized form, is sufficient for maintaining quality under proper storage conditions.

98.5% vs. 99% Purity: Both grades go through our lyophilization process in our US-based facility and are tested for quality at a third party lab. While the 99%+ purity grade is our highest reference grade product line, the 98.5% purity variants still exceed US pharmaceutical standards.

Product Overview

Description
COA
Storage

What is BPC-157?

BPC-157, short for Body Protection Compound-157, is a derivative of a naturally occurring protein in the digestive tract that promotes healing, protects the GI lining, and stimulates blood vessel growth.

  • Wound healing
  • Blood vessel growth
  • The coagulation cascade
  • Nitric oxide generation
  • Immune system function
  • Gene expression
  • Hormone regulation

BPC-157 Peptide Structure

BPC-157 Peptide Structure

Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Molecular Formula: C62H98N16O22
Molecular Weight: 1419.556 g/mol
PubChem CID: 108101

BPC-157 Peptide Research

  • Wound Healing: Promotes fibroblast activity and extracellular matrix repair.
  • Vascular Growth: Stimulates angiogenesis and collateral blood vessel formation.
  • Tendon Healing: Improves tendon, ligament, and bone healing.
  • Antioxidant Properties: Neutralizes oxidative stress and supports GI health.
  • Drug Side Effects: Counters NSAID-induced damage and protects against arrhythmias.
  • Bee Research: Shown to improve honeybee gut health and hive survival.

Future BPC-157 Research

Ongoing research is investigating its roles in angiogenesis, cancer development, and embryogenesis, highlighting its wide therapeutic potential.

Referenced Citations

  1. T. Huang et al., “Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro,” Drug Des. Devel. Ther., vol. 9, pp. 2485–2499, 2015.
  2. D. Drmic et al., “Counteraction of perforated cecum lesions in rats: Effects of pentadecapeptide BPC 157, L-NAME and L-arginine,” World J. Gastroenterol., vol. 24, no. 48, pp. 5462–5476, Dec. 2018.
  3. F. Amic et al., “Bypassing major venous occlusion and duodenal lesions in rats, and therapy with the stable gastric pentadecapeptide BPC 157, L-NAME and L-arginine,” World J. Gastroenterol., vol. 24, no. 47, pp. 5366–5378, Dec. 2018.
  4. A. Duzel et al., “Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: New insights,” World J. Gastroenterol., vol. 23, no. 48, pp. 8465–8488, Dec. 2017.
  5. J. Vukojević et al., “Rat inferior caval vein (ICV) ligature and particular new insights with the stable gastric pentadecapeptide BPC 157,” Vascul. Pharmacol., vol. 106, pp. 54–66, 2018.
  6. D. Drmic et al., “Celecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME,” World J. Gastroenterol., vol. 23, no. 29, pp. 5304–5312, Aug. 2017.
  7. M.-J. Hsieh et al., “Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation,” J. Mol. Med. Berl. Ger., vol. 95, no. 3, pp. 323–333, 2017.
  8. Z. Grabarevic et al., “The influence of BPC 157 on nitric oxide agonist and antagonist induced lesions in broiler chicks,” J. Physiol. Paris, vol. 91, no. 3–5, pp. 139–149, Oct. 1997.
  9. P. Sikiric et al., “Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing,” Curr. Pharm. Des., vol. 24, no. 18, pp. 1990–2001, 2018.
  10. S. Seiwerth et al., “BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing,” Curr. Pharm. Des., vol. 24, no. 18, pp. 1972–1989, 2018.
  11. C.-H. Chang et al., “The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration,” J. Appl. Physiol., vol. 110, no. 3, pp. 774–780, Oct. 2010.
  12. Y.-L. Hu et al., “FAK and paxillin dynamics at focal adhesions in the protrusions of migrating cells,” Sci. Rep., vol. 4, p. 6024, Aug. 2014.
  13. K. Škrlec et al., “Engineering recombinant Lactococcus lactis as a delivery vehicle for BPC-157 peptide with antioxidant activities,” Appl. Microbiol. Biotechnol., vol. 102, no. 23, pp. 10103–10117, Dec. 2018.
  14. D. Strinic et al., “BPC 157 counteracts QTc prolongation induced by haloperidol, fluphenazine, clozapine, olanzapine, quetiapine, sulpiride, and metoclopramide in rats,” Life Sci., vol. 186, pp. 66–79, Oct. 2017.
  15. N. Jelovac et al., “Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats,” Eur. J. Pharmacol., vol. 379, no. 1, pp. 19–31, Aug. 1999.
  16. I. Tlak Gajger et al., “Stable gastric pentadecapeptide BPC 157 in honeybee (Apis mellifera) therapy, to control Nosema ceranae invasions in apiary conditions,” J. Vet. Pharmacol. Ther., vol. 41, no. 4, pp. 614–621, Aug. 2018.

COA

Below are the Certificates of Analysis confirming the purity and quality of our BPC-157:

BPC-157 COA 1 BPC-157 COA 2 BPC-157 COA 3

Storage Instructions

All of our products are manufactured using the Lyophilization (Freeze Drying) process, which ensures that our products remain 100% stable for shipping for up to 3–4 months.

Once the peptides are reconstituted (mixed with bacteriostatic water), they must be stored in the refrigerator to maintain stability. After reconstitution, the peptides will remain stable for up to 30 days.

Lyophilization is a unique dehydration process, also known as cryodesiccation, where the peptides are frozen and then subjected to low pressure. This causes the water in the peptide vial to sublimate directly from solid to gas, leaving behind a stable, crystalline white structure known as lyophilized peptide. The puffy white powder can be stored at room temperature until you're ready to reconstitute it with bacteriostatic water.

Once peptides have been received, it is imperative that they are kept cold and away from light. If the peptides will be used immediately, or in the next several days, weeks, or months, short-term refrigeration under 4°C (39°F) is generally acceptable. Lyophilized peptides are usually stable at room temperatures for several weeks or more, so if they will be utilized within weeks or months, such storage is typically adequate.

For longer-term storage (several months to years), it is preferable to store peptides in a freezer at -80°C (-112°F). When storing peptides for months or even years, freezing is optimal to preserve the peptide’s stability.

For further information on proper storage techniques, click the link below:

Peptide Storage Information

All products offered by TheraTide USA are strictly intended for research and development purposes only.

None of the statements on this website have been evaluated by the U.S. Food and Drug Administration. Our products are not intended to diagnose, treat, cure, or prevent any disease.

TheraTide USA is a research chemical supplier. We are not a compounding pharmacy or a chemical compounding facility as defined under Section 503A of the Federal Food, Drug, and Cosmetic Act.